Comments, Opinions, and Brief Case Reports
February 25, 2002

Aspirin, Postmenopausal Hormones, and C-Reactive Protein

Author Affiliations

Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002

Arch Intern Med. 2002;162(4):480-481. doi:

Most oral preparations of postmenopausal hormones (PMHs) increase levels of C-reactive protein (C-RP), a sensitive marker of inflammation, within about 4 weeks of initiation of therapy.13 This increase is observed in patients who are given either estrogen alone or estrogen in combination with a progestin, which has now become the most common preparation of PMH used. These data derive from observational studies and randomized trials of apparently healthy women suggesting that the increase is not attributable to atherosclerotic burden or other risk factors for cardiovascular disease or to other inflammatory disorders.4

First Page Preview View Large
First page PDF preview
First page PDF preview